Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach

major pathological response rate

The proportion of subjects with surviving tumor cells ≤10% in total subjects;

Time frame: within 10 days after surgery

Objective response rate

Proportion of patients who achieved pre-defined tumor volume reduction , including patients with complete response (CR) and partial response (PR).

Time frame: From enrollment to surgery, assessed up to 3 months

Event-free survival

From the start of treatment to the first occurrence of any of the following events: disease progression without surgical treatment, local or distant recurrence, death from any cause

Time frame: From date of enrollment until the date of first documented progression, recurrence or date of death from any cause, whichever came first, assessed up to 3 years

Disease free survival

It usually starts from the time when the patient receives treatment (such as surgery), and ends at the time when the disease recurs (such as tumor recurrence, metastasis) or when the patient dies for any reason

Time frame: From date of surgery until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 3 years

overall survival

It refers to the period from when the patient is diagnosed until death due to any cause.

Time frame: From date of diagnosis until the date of death from any cause, assessed up to 3 years